Medtronic Reports Record Q1 Revenue of $9.76 Billion and Announces $780 Million in Strategic Investments

Recently, according to foreign media reports, Medtronic delivered a first-quarter fiscal 2027 performance that far exceeded market expectations. On the same day, Medtronic announced two strategic investments totaling $780 million.

Image source: Latest Medical Device News on MassDevice

Earnings Beat Expectations and Major Investment Announced on Same Day: Where Did Medtronic Invest Its Profits?

First, let's look at Medtronic's Q1 2027 financial results. The financial report shows that as of July 31, 2026,Medtronic Achieves Revenue of $9.756 Billion, a 13.7% Year-over-Year Increase；GAAPNet profit reached $1.47 billion, a significant year-on-year increase of 41.4%.

By business segment,Medtronic Achieved Double-Digit Revenue Growth Across All Major Business Segments. Cardiovascular Business Revenue Reached $3.927 Billion, a Year-on-Year Increase of 19.5%., accounting for 40% of total revenue. Among them, including pulsed field ablation (PFA) The company’s Cardiac Ablation Solutions (CAS) business delivered particularly strong performance, with an 88% year-over-year growth, including a remarkable 139% surge in the U.S. market. Notably, the CAS business has maintained robust momentum in recent years, with the new-generation pulsed field ablation (PFA) platform—represented by the Affera 3D mapping system and the Sphere-9 dual-energy catheter—rapidly scaling up in volume.

Neuroscience business revenue reached $2.678 billion, an increase of 10.3%;Surgical BusinessRevenue amounted to $2.279 billion, representing a 10.0% increase. The remaining revenue was derived from Medtronic inDiabetes Businessits stake in (now the independently listed company MiniMed), with revenue of $843 million, a year-on-year increase of 16.9%; this business is expected to complete its spin-off by the end of the current fiscal year.

Based on strong Q1 performance, Medtronic raised its full-year organic revenue growth guidance from the previous 6.75%-7.25% to 7.25%-7.75%.

On the same day as the financial report release,Medtronic Announces Collaboration with Innovative Chinese Medical Device CompaniesCornerstone RoboticsStrategic investment of approximately $700 million.Under the agreement, Medtronic will obtainCornerstone Robotics' Sentire^®Laparoscopic Surgical RobotDistribution rights in certain approved markets outside the United States.

According to the Yaozhi Medical Device Data Query,Currently, Cornerstone Robotics has 10 products on the market., among which the aforementioned surgical robotSentireApproved for market launch by China’s NMPA in 2024, and obtained EU CE marking and Singapore HSA approval in May 2026, covering minimally invasive surgical fields such as urology, general surgery, gynecology, and thoracic surgery.

Image source: Yaozhi Medical Device Data

Sentire will partner with Medtronic'sHugo PlatformForming a dual-platform portfolio. Furthermore, Medtronic expects that by the end of this fiscal year, the cumulative global number of procedures performed with the Hugo system will exceed 50,000, with procedure volume growth remaining at more than twice the market growth rate.

Another $80 million investment was directed by Medtronic toward the TAVR sector, specificallyInvestment in the Israeli Company Pi-CardiaPi-Cardia's core product, ShortCut, isThe World’s First Leaflet Repair Technology Approved by the U.S. FDA, specifically designed to prevent the risk of coronary artery obstruction during transcatheter valve-in-valve TAVR procedures.

Under the agreement, Medtronic will make a strategic investment of up to $80 million in Pi-Cardia and is expected to become the exclusive global commercial distributor for the ShortCut product by 2027. The agreement also includes an acquisition option: upon achieving predefined milestones, Medtronic has the right to acquire Pi-Cardia for an estimated initial consideration of no more than $210 million.